{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:36:24Z","timestamp":1790987784992,"version":"4.1.0"},"reference-count":27,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2006,10,2]],"date-time":"2006-10-02T00:00:00Z","timestamp":1159747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2006,10,2]],"date-time":"2006-10-02T00:00:00Z","timestamp":1159747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Arch Allergy Immunol"],"published-print":{"date-parts":[[2007]]},"abstract":"<jats:p>&lt;i&gt;Background:&lt;\/i&gt; The anti-inflammatory actions of acetylsalicylic acid (ASA)\/non-steroidal anti-inflammatory drugs (NSAIDs) are thought to be due to inhibition of COX-2, whereas the side effects such as gastric damage and aspirin-induced asthma are mediated through inhibition of COX-1. Therefore, a new class of drugs with COX-2 selectivity may be well tolerated by patients with ASA\/NSAIDs hypersensitivity. &lt;i&gt;Objective:&lt;\/i&gt; We investigated whether subjects with asthma and\/or nasal polyps (NP) and analgesic intolerance proven by oral ASA provocation test tolerated the selective COX-2 inhibitor, meloxicam. &lt;i&gt;Methods:&lt;\/i&gt; All subjects were first challenged with ASA using a 2-day, single-blind, placebo-controlled oral provocation test. Thereafter, the subjects showing positive response to ASA provocation underwent a single-blind, placebo-controlled challenge with a cumulative dose of 7.5 mg of meloxicam on 2 separate days. One and three fourths of the divided doses of placebo and the active drug were given at 1-hour intervals. Clinical symptoms, lung function, and blood pressure were monitored during these challenge protocols. &lt;i&gt;Results:&lt;\/i&gt; Twenty-one patients with asthma and\/or NP (10 males and 11 females; mean age: 38.4 \u00b1 2.9 years) who reacted to ASA challenges were enrolled in the study. Response to ASA provocation was rhinitis + bronchospasm in 13, and extrabronchial reactions in 8 (isolated rhinitis in 3) patients. Mean PD&lt;sub&gt;20&lt;\/sub&gt; was 163.4 \u00b1 39.9 mg ASA among patients who reacted with bronchospasm to ASA. Only 1 patient reacted to meloxicam challenge at a cumulative dose of 7.5 mg. &lt;i&gt;Conclusion:&lt;\/i&gt; This study indicates that 7.5 mg of meloxicam is a safe alternative treatment for ASA-hypersensitive asthma and\/or NP patients with proven hypersensitivity via oral ASA challenges.<\/jats:p>","DOI":"10.1159\/000096000","type":"journal-article","created":{"date-parts":[[2006,10,5]],"date-time":"2006-10-05T06:09:01Z","timestamp":1160028541000},"page":"64-69","source":"Crossref","is-referenced-by-count":41,"title":["Safety of Meloxicam in Aspirin-Hypersensitive Patients with Asthma and\/or Nasal Polyps"],"prefix":"10.1159","volume":"142","author":[{"given":"Sevim","family":"Bavbek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Berna","family":"Dursun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Engin","family":"Dursun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil","family":"Ery\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep","family":"M\u0131s\u0131rl\u0131gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2006,10,2]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007%2Fs11882-004-0037-x"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1067%2Fmai.2003.1487"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.jaci.2003.12.323"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2165%2F00003495-200363010-00003"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1046%2Fj.1365-2222.2001.01075.x"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1067%2Fmai.2000.110926"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1067%2Fmai.2001.116290"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1081%2FJAS-200051326"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016%2FS1081-1206%2810%2961282-3"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1034%2Fj.1398-9995.2001.00300.x"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1067%2Fmai.2002.121315"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJM200112203452518"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJMoa050493"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJMe058042"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1081%2FJAS-120026063"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016%2FS1081-1206%2810%2962412-X"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1034%2Fj.1398-9995.2002.13447.x"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1067%2Fmai.2003.1450"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1034%2Fj.1399-3003.2000.15e09.x"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3109%2F02770909909075412"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007%2FBF02735467"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1398-9995.1998.tb03854.x"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1034%2Fj.1399-3003.2000.016003432.x"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1097%2F01.all.0000010981.95396.58"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1398-9995.1996.tb00004.x"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016%2FS1081-1206%2810%2962748-2"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1398-9995.1998.tb03995.x"}],"container-title":["International Archives of Allergy and Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/96000","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/96000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T02:48:05Z","timestamp":1745462885000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000096000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10,2]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2006,12,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000096000","archive":["Portico"],"relation":{},"ISSN":["1018-2438","1423-0097"],"issn-type":[{"value":"1018-2438","type":"print"},{"value":"1423-0097","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10,2]]}}}